These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25828306)

  • 1. Blockade of mTOR pathway inhibition in the neointimal hyperplasia and promoting macrophage autophagy - Effect of statin-eluting stents to reduce in-stent restenosis.
    Hu HJ; Zhou SH; Liu QM
    Int J Cardiol; 2015; 187():31-2. PubMed ID: 25828306
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of human in-stent restenosis: a molecular view.
    Giordano A; Romano A
    Curr Opin Pharmacol; 2011 Aug; 11(4):372-7. PubMed ID: 21497134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: an optical coherence tomographic study.
    Nakamura D; Lee Y; Yoshimura T; Taniike M; Makino N; Kato H; Egami Y; Shutta R; Tanouchi J; Yamada Y; Hara M; Sakata Y; Hamasaki T; Nishino M
    EuroIntervention; 2014 Dec; 10(8):924-33. PubMed ID: 24602858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental study of Mytrolimus-eluting stents on preventing restenosis in porcine coronary model].
    Qiu H; Gao RL; Tang ZR; Meng L; Zhao H; Ruan YM; Zhao H; Yang YJ; Chen JL; Chen ZJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Jun; 33(6):561-4. PubMed ID: 16053797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents.
    Moore P; Barlis P; Spiro J; Ghimire G; Roughton M; Di Mario C; Wallis W; Ilsley C; Mitchell A; Mason M; Kharbanda R; Vincent P; Sherwin S; Dalby M
    JACC Cardiovasc Interv; 2009 May; 2(5):437-44. PubMed ID: 19463468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis.
    Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C
    Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Genous™ endothelial progenitor cell capture stent accelerates stent re-endothelialization but does not affect intimal hyperplasia in porcine coronary arteries.
    van Beusekom HM; Ertaş G; Sorop O; Serruys PW; van der Giessen WJ
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):231-42. PubMed ID: 21834062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do statins have a role in reduction/prevention of post-PCI restenosis?
    Prasad K
    Cardiovasc Ther; 2013 Feb; 31(1):12-26. PubMed ID: 21967674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: in vivo assessment with optical coherence tomography.
    Gutiérrez-Chico JL; Räber L; Regar E; Okamura T; di Mario C; van Es GA; Windecker S; Serruys PW
    Am Heart J; 2013 Jul; 166(1):83-94. PubMed ID: 23816026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
    Martinet W; De Loof H; De Meyer GRY
    Atherosclerosis; 2014 Apr; 233(2):601-607. PubMed ID: 24534455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse association of coronary soluble tumor necrosis factor-related apoptosis inducing ligand (sTRAIL) levels to in-stent neointimal hyperplasia.
    Deftereos S; Giannopoulos G; Panagopoulou V; Raisakis K; Kossyvakis C; Kaoukis A; Tzalamouras V; Mavri M; Pyrgakis V; Cleman MW; Stefanadis C
    Cardiology; 2012; 123(2):97-102. PubMed ID: 23018671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study.
    Chieffo A; Buchanan GL; Parodi G; Versaci F; Bianchi RM; Valenti R; Saccà S; Mongiardo A; Span S; Migliorini A; Spaccarotella C; Reimers B; Antoniucci D; Indolfi C; Ferrari A; Maehara A; Mintz GS; Colombo A
    EuroIntervention; 2014 Dec; 10(8):916-23. PubMed ID: 24974806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neointimal reaction in overlap segments of drug-eluting stents: is it "one-size-fits-all"?
    Nammas W
    Am Heart J; 2013 Oct; 166(4):e29. PubMed ID: 24093867
    [No Abstract]   [Full Text] [Related]  

  • 15. In-stent restenosis is associated with neointimal angiogenesis and macrophage infiltrates.
    Zhang M; Cresswell N; Tavora F; Mont E; Zhao Z; Burke A
    Pathol Res Pract; 2014 Dec; 210(12):1026-30. PubMed ID: 24815534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.
    Jaschke B; Michaelis C; Milz S; Vogeser M; Mund T; Hengst L; Kastrati A; Schömig A; Wessely R
    Cardiovasc Res; 2005 Dec; 68(3):483-92. PubMed ID: 16111664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.
    Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in neointimal hyperplasia following endeavor zotarolimus-eluting stent implantation.
    Nakatani D; Ako J; Tremmel JA; Waseda K; Otake H; Koo BK; Miyazawa A; Hongo Y; Hur SH; Sakurai R; Yock PG; Honda Y; Fitzgerald PJ
    Am J Cardiol; 2011 Oct; 108(7):912-7. PubMed ID: 21784390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should We Up the Intensity of Statin Therapy After Placing a Drug-eluting Stent?
    Parikh KH; Kirtane AJ
    Rev Esp Cardiol (Engl Ed); 2018 Jun; 71(6):416-417. PubMed ID: 29104001
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.
    Kim S; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Cho YK; Nam CW; Hur SH; Jang Y; Hong MK
    Am J Cardiol; 2013 Jan; 111(1):1-5. PubMed ID: 23040589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.